The recommendation builds on the committee’s June 2024 vote for the use of RSV vaccines for people aged 60 to 74 at high risk ...

A key group of government advisers voted to expand the use of vaccines for a common respiratory illness, providing a boost to ...

A CDC committee has voted to expand its respiratory syncytial virus vaccine recommendation to include all people aged 50 to ...

On Wednesday, the Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of ...

The committee endorsed lowering the age at which some people can receive RSV vaccines, but stopped short of recommending booster shots.

A year after narrowing its recommendation for who should use vaccines to defend against respiratory syncytial virus (RSV), a ...

A panel of federal health experts on Wednesday recommended expanded vaccine options for several diseases, including ...

A three-year study has found robust evidence that one particular vaccine for respiratory syncytial virus (RSV) offers older ...

For meningococcal vaccines, ACIP recommended that GSK's pentavalent vaccine (Penmenvy), designed to protect against A, B, C, ...

Although we can’t control what others chose to do about handwashing and social distancing, we can decide to protect our ...

Arexvy, already approved in over 60 countries, was supported by trial data showing safety and immune response in the 50–59 age group. GSK said more than 13 million adults in the US fall into this ...

After decades of fits and starts, scientists finally got the world’s first vaccines against respiratory syncytial virus ...